BeiGene Ltd. Gains FDA Approval for TEVIMBRA® in Advanced Gastric Cancer Treatment
- BeiGene secures FDA approval for TEVIMBRA® as a first-line treatment for HER2-negative gastric cancer.
- TEVIMBRA shows a 20% reduction in death risk, improving overall survival in clinical trials.
- The approval reflects BeiGene's commitment to advancing oncology treatments and improving patient outcomes.
BeiGene Secures FDA Approval for TEVIMBRA® in Gastric Cancer Treatment
BeiGene, Ltd., soon to be rebranded as BeOne Medicines Ltd., achieves a notable milestone in oncology with the U.S. Food and Drug Administration's (FDA) approval of TEVIMBRA® (tislelizumab-jsgr) for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults. This approval is significant, particularly for patients whose tumors express PD-L1 at a level of 1% or higher. Mark Lanasa, M.D., Ph.D., Chief Medical Officer at BeiGene, underscores the importance of this approval in improving treatment options for cancer patients, marking a vital step in the fight against this challenging malignancy.
The approval is based on positive outcomes from the RATIONALE-305 Phase 3 trial, which evaluates the efficacy of TEVIMBRA when combined with chemotherapy. The study shows a median overall survival (OS) of 15.0 months for patients receiving the combination therapy, compared to 12.9 months for those in the placebo group. This promising data translates to a 20% reduction in the risk of death, highlighting TEVIMBRA's potential as a valuable treatment option in a therapeutic landscape that has few alternatives for this patient population. With a participant cohort of 997 and a hazard ratio of 0.80 (P=0.0011), the trial results provide compelling evidence for the drug's effectiveness.
Safety data for TEVIMBRA comes from a comprehensive analysis of 1,972 patients across various studies. While the drug shows promise, it is essential to acknowledge the common Grade 3 or 4 adverse reactions reported, including neutropenia, thrombocytopenia, and anemia. Notably, this approval marks the second for TEVIMBRA in 2023, as it is already authorized for the treatment of unresectable or metastatic esophageal squamous cell carcinoma (ESCC) in adult patients following chemotherapy. This dual approval reflects BeiGene’s commitment to addressing significant oncology needs and aims to harness this momentum for future advancements in cancer therapies.
In addition to the recent approval, BeiGene expresses gratitude to the patients, clinicians, and researchers who contributed to the development of TEVIMBRA. The company remains focused on its mission to deliver transformative cancer therapies and improve patient outcomes in a field where effective treatment options are often limited. As BeiGene transitions to BeOne Medicines Ltd., it continues to prioritize innovation and collaboration in its quest to redefine cancer care.